Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Shares Bought by VELA Investment Management LLC

VELA Investment Management LLC increased its holdings in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 54.5% during the 4th quarter, HoldingsChannel reports. The fund owned 148,112 shares of the company’s stock after acquiring an additional 52,246 shares during the quarter. VELA Investment Management LLC’s holdings in Maravai LifeSciences were worth $807,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of MRVI. FNY Investment Advisers LLC lifted its stake in shares of Maravai LifeSciences by 600.0% in the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after acquiring an additional 6,000 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of Maravai LifeSciences in the third quarter worth about $47,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Maravai LifeSciences in the third quarter worth about $105,000. Neo Ivy Capital Management acquired a new position in shares of Maravai LifeSciences in the third quarter worth about $136,000. Finally, Patriot Financial Group Insurance Agency LLC acquired a new position in shares of Maravai LifeSciences in the fourth quarter worth about $136,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analyst Weigh In

MRVI has been the topic of several recent analyst reports. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the stock from $7.00 to $4.25 in a research note on Thursday, December 5th. William Blair reissued a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Royal Bank of Canada lowered their price objective on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a report on Friday, November 8th. Wolfe Research initiated coverage on Maravai LifeSciences in a report on Thursday, November 14th. They set a “peer perform” rating for the company. Finally, Baird R W lowered Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.46.

Maravai LifeSciences Stock Performance

Shares of MRVI stock opened at $3.05 on Friday. Maravai LifeSciences Holdings, Inc. has a 12-month low of $2.93 and a 12-month high of $11.56. The firm has a market capitalization of $770.21 million, a price-to-earnings ratio of -1.86 and a beta of -0.08. The business has a 50 day simple moving average of $4.88 and a 200 day simple moving average of $6.52. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94.

Insider Buying and Selling

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the sale, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.63% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.